ABOUT US
Curespec is ushering in a new era of hope for chronic kidney disease (CKD) and hypertensive patients with Nephrospec™, our cutting-edge technology.
We stand as pioneers, offering a life-extending treatment that revitalizes kidneys, delays the need for dialysis, and lowers blood pressure, all while making significant cost savings for healthcare systems.
Nephrospec™ is a safe, non-invasive low intensity electro-Hydraulic Acoustic Therapy (eHAT) device for the treatment of CKD and hypertension.
Our patented technology promotes new blood vessel formation and restores damaged tissue function while saving up to 80% of the costs associated with dialysis.
Nephrospec™ by Curespec:
A complementary solution to optimize medical care for CKD and hypertension
Improvement of kidney function within a few weeks
Delayed onset of outpatient treatment for dialysis
OUR PRODUCT
Pre treatment
ARAS Kidney
Post Nephrospec™ treatment
Curespec uses electro-Hydro Acoustic Therapy to produce a neovascularization effect on the kidneys
CLINICAL APPLICATIONS
Low–Energy Shockwave Therapy Improves Ischemic Kidney Microcirculation
Zhang X, Krier JD, Carrascal CA, et al.
J Am Soc Nephrol. 2016; 27(12):3715-3724.
Low-Energy Shockwave Treatment Promotes Endothelial Progenitor Cell Homing to the Stenotic Pig Kidney
Zhao Y, Santelli A, Zhu XY, et al.
Cell Transplant. 2020; 29.
It Comes As a Shock
Kidney Repair Using Shockwave Therapy
Klomjit N, Lerman A, Lerman LO.
Hypertension. Published online 2020:1696-1703.
Magnetic resonance elastography can monitor changes in medullary stiffness in response to treatment in the swine ischemic kidney
Zhang X, Zhu X, Ferguson CM, et al.
Magn Reson Mater Physics, Biol Med. 2018; 31(3):375-382.
Adjunctive mesenchymal stem / stromal cells augment microvascular function in poststenotic kidneys treated with low-energy shockwave therapy
Chen X-J, Zhang X, Jiang K, et al
J Cell Physiol. 2020; 235(12):9806-9818.
Innovation in Cardiovascular Interventions Meeting:
First results using a new renal restoration approach to treat hypertension and preserve renal function in CKD patients - Presented by Prof. Talya Wolak
Our Team
Avner Spector
Founder, Active Chairman
Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies.
Rotem Kaynan
CEO
Mr. Kaynan is a Biomedical Engineer. More than 20 years of experience in Medical Devices, leading teams of clinical applications, sales & product management.
Sandra Morgan
Executive Advisor
Ms. Morgan has over 32 years in healthcare with Fortune 100 companies including HCA Healthcare and Pfizer. In the past she was an executive at HCA Healthcare responsible for business growth through physicians and service lines. In her last role at Pfizer, Sandra led the US managed care team responsible for achieving formulary status for Pfizer’s portfolio.
Advisory Board
Lilach O. Lerman, MD, PhD
The Arthur M. and Gladys D. Gray Professor in Honor of Dr. Howard A. Andersen Professor of Medicine and Physiology Director, Reno- Vascular Research Laboratory Division of Nephrology and Hypertension Mayo Clinic
Amir Lerman, M.D.
Barbara Woodward Lips Professor
Associate Chair, Cardiovascular Medicine Director - Cardiovascular Research Center Consultant, Department of Cardiovascular Medicine Mayo Clinic
203 Perry Pkwy, Suite # 6 Gaithersburg, MD 20877-2169, USA
Office 301.944.1575